Johnson & Johnson Sales Rose to $25.4 Billion in Q3
Healthcare operators should track how J&J's pivot toward high-growth pharmaceuticals like Tremfya impacts product portfolios.
Updated on Oct. 13, 2026 in Healthcare
Live Poll
Do you trust that high-priced specialty drugs provide enough value to justify their costs?
Johnson & Johnson reported $25.4 billion in total sales for the third quarter of 2026, driven by strong performance in its pharmaceutical division. The company also raised its full-year 2026 sales and earnings guidance despite acquisition costs and legal settlements.
Why it matters
The results demonstrate how diversified healthcare firms manage product lifecycle shifts, specifically offsetting declining revenues from legacy immunology products with high-growth specialized therapies. This transition requires careful monitoring of capital allocation strategies.
Johnson & Johnson recorded $25.4 billion in Q3 revenue with pharma sales reaching $16.8 billion. Tremfya sales grew 68.3% to $2.4 billion, while the company maintains a midpoint sales growth projection of 6.6% for 2026.
The players
Johnson & Johnson
A global healthcare conglomerate that develops medical devices, pharmaceuticals, and consumer-facing health products.
Tremfya
A high-growth pharmaceutical therapy for plaque psoriasis that serves as a core revenue driver for the company.
Shockwave
A specialized cardiovascular medical technology business acquired by Johnson & Johnson in 2024.
Firefly Bio
A biotechnology developer acquired by Johnson & Johnson in July 2026 to expand the pharma pipeline.
The details
Growth in the medicine segment was primarily powered by a 68.3% surge in Tremfya sales, which helped balance out a 54.4% decline in Stelara revenue. Medtech operations saw worldwide sales growth of 2.5%, anchored by a 16.8% increase in Shockwave performance. Meanwhile, total earnings per share were impacted by costs related to the company's recent $1 billion acquisition of Firefly Bio and talcum powder lawsuit settlements.
Timeline
2017: FDA approved Tremfya for plaque psoriasis.
2024: Johnson & Johnson acquired Shockwave for $13.1 billion.
July 2026: J&J acquired Firefly Bio for $1 billion.
Q3 2026: Financial reporting period for quarterly results.
Market Landscape
This performance follows the pattern established by the 2024 acquisition of Shockwave, which continues to drive growth in the company's Medtech division. The strategy reflects a broader trend of large-cap healthcare firms acquiring specialized assets to hedge against the loss of exclusivity for legacy drugs.
Operators should evaluate how their own product mixes account for legacy product erosion versus new growth drivers. Focus should remain on the fiscal midpoint projections of 6.6% annual sales growth as a benchmark for sector performance in 2026.
The takeaway
Large-scale diversification remains the primary defense against the rapid decline of individual product revenues. Monitor quarterly guidance updates as a signal for broader healthcare market confidence.
Further reading
For more on industry shifts in pharmaceutical product lifecycles, visit our Healthcare section.
Live Poll
Do you trust that high-priced specialty drugs provide enough value to justify their costs?
